This Medudy course is a video tutorial for physicians on the topic “CheckMate 214: 9-Year Follow-Up.”
Professor Günter Niegisch, Head of the Department of Conservative Urological Oncology at Düsseldorf University Hospital, presents the long-term data from the CheckMate 214 study.
The study compared the dual immunotherapy combination of nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) with the current standard of care, sunitinib. The presentation focuses in particular on demonstrating the sustained overall survival benefit achieved with the combination regimen. These results are of critical importance for clinical decision-making, particularly for patients with advanced renal cell carcinoma (aRCC) who have an intermediate or high-risk profile.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was created with the kind support of BMS.
By the end of this training, you will know/understand:
- the key findings of the registration-relevant CheckMate 214 trial regarding 9-year overall survival and efficacy.
- how the combination of nivolumab and ipilimumab compares to sunitinib in terms of long-term clinical benefit in advanced renal cell carcinoma (aRCC).
- the importance of a sustained, long-term survival rate achieved with dual immunotherapy, particularly among intermediate- and high-risk aRCC patients.
- the clinical implications of these extended follow-up data for current treatment decisions and patient counseling.
